List of publications

All the publications of the C3M teams.

Export in CSV
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Authors Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S

PloS one Jul 2012

Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Authors Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C

The Journal of biological chemistry Jul 2012

Proper macrophagic differentiation requires both autophagy and caspase activation.

Authors Jacquel A, Obba S, Solary E, Auberger P

Autophagy Jul 2012

Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.

Authors Meynet O, Bénéteau M, Jacquin MA, Pradelli LA, Cornille A, Carles M, Ricci JE

Leukemia May 2012

PPARs: Interference with Warburg’ Effect and Clinical Anticancer Trials.

Authors Vamecq J, Colet JM, Vanden Eynde JJ, Briand G, Porchet N, Rocchi S

PPAR research May 2012

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.

Authors Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R

Oncogene May 2012

Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions.

Authors Jacquel A, Obba S, Boyer L, Dufies M, Robert G, Gounon P, Lemichez E, Luciano F, Solary E, Auberger P

Blood May 2012

Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.

Authors Fenouille N, Grosso S, Yunchao S, Mary D, Pontier-Bres R, Imbert V, Czerucka D, Caroli-Bosc FX, Peyron JF, Lagadec P

The Journal of pathology May 2012

BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Authors Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P

Oncotarget Apr 2012

Prevention of mutagenesis: new potential mechanisms of metformin action in neoplastic cells.

Authors Bost F, Ben-Sahra I, Tanti JF

Cancer prevention research (Philadelphia, Pa.) Apr 2012